Forbes included Israeli pharmaceutical firm Teva on its ranking of 130 “global superstars.” Ynet reported Monday that the Forbes shortlist, a lead-up to its annual “Global 2,000” ranking, is based on a combination of the firms’ sales, profits, assets and market value. In 2006, Teva registered $8.41 billion in sales, $55 million in profits, $20.47 billion in assets and a market value of $26.91 billion.
Reporting the stories that define our era. When history unfolds in real-time, the Jewish world turns to JTA. Your support ensures we can document the complexities of war and the resilience of Jewish communities with integrity.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
